New Technologies for CAR-T and Solid Tumor Research
Advancing CAR-T therapy with flow cytometry and live-cell imaging
Selecting the optimal antigen for chimeric antigen receptor T-cell (CAR-T) therapy is difficult due to the heterogeneity of solid tumors. To advance CAR-T therapy and solid tumor research, scientists are developing novel technologies to rapidly screen hundreds of novel target antigens from different subpopulations of tumor cells. Using advanced flow cytometry platforms and automated live-cell analysis, researchers easily identify optimal target antigens by screening numerous samples.
Download this ebook from Sartorius to learn more about
- Rapidly identifying target antigens for solid tumors
- Developing next-generation profiling solutions for CAR-T research with flow cytometry and live-cell imaging
- The importance of accurate analyses and validation of high-throughput CAR-T screening data
- Optimizing laboratory techniques for best CAR-T screening results
